Patients are randomized to 1 of 3 treatment groups for 24 weeks. Treatment will be blinded to investigator and patient, but not to the sponsor. All 3 groups also receive nelfinavir mesylate and 2 NRTIs. All patients receive the same dose of nelfinavir mesylate. The NRTIs are selected at the investigator's discretion provided the patient has not previously received the chosen NRTIs.
Patients have regular physical examinations.
Blood samples are collected regularly and at 1 month post-treatment to determine plasma HIV RNA, pharmacokinetics, and CD4 and CD8 counts. Patients who complete 24 weeks of treatment will have the option to continue treatment for an additional 24 weeks or end participation. Treatment will be blinded to investigator and patient, but not to the sponsor. All 3 groups also receive nelfinavir mesylate and 2 NRTIs. All patients receive the same dose of nelfinavir mesylate.